Literature DB >> 25957581

Emergence and spread of O16-ST131 and O25b-ST131 clones among faecal CTX-M-producing Escherichia coli in healthy individuals in Hunan Province, China.

Yi-Ming Zhong1, Wen-En Liu2, Xiang-Hui Liang1, Yan-Ming Li1, Zi-Juan Jian1, Peter M Hawkey3.   

Abstract

OBJECTIVES: The objectives of this study were to determine CTX-M-producing Escherichia coli ST131 strain prevalence in stool specimens from healthy subjects in central China and to molecularly characterize clonal groups.
METHODS: From November 2013 to January 2014, stool specimens from healthy individuals in Hunan Province were screened for ESBL-producing E. coli using chromogenic medium and CTX-M genotypes and phylogenetic groups were determined. ST131 clonal groups were detected by PCR and characterized for antibiotic resistance, fimH, gyrA and parC alleles, plasmid-mediated quinolone resistance determinants, virulence genotypes and PFGE patterns.
RESULTS: Among 563 subjects, 287 (51.0%) exhibited the presence of faecal ESBL-producing E. coli, all of which produced CTX-M enzymes. The most common CTX-M genotypes were CTX-M-14 (48.4%), CTX-M-15 (27.5%) and CTX-M-27 (15.0%). Of the 287 CTX-M-producing isolates, 32 (11.1%) belonged to the ST131 clone. O16-ST131 isolates were dominant (75%) and contained the fimH41 allele. The remaining eight (25%) ST131 isolates were of the O25b subgroup and contained fimH30 or fimH41. Ciprofloxacin resistance was found in 100% of the O25b-ST131 isolates, whereas only 8% of the O16-ST131 isolates were resistant. All of the O25b-ST131 isolates except one showed gyrA1AB and parC1aAB mutations; most of the O16-ST131 isolates had gyrA1A and parC1b mutations. The virulence genotypes of O16-ST131 resembled those of the O25b-ST131 isolates. The 32 ST131 isolates formed one large group at the 64% similarity level. They comprised 15 PFGE groups (defined at ≥85% similarity).
CONCLUSIONS: O16-ST131 isolates have emerged as the predominant type of ST131 isolate in faecal CTX-M-producing E. coli in healthy individuals in China.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Entities:  

Keywords:  E. coli; ESBLs; faecal carriage; genotypes

Mesh:

Substances:

Year:  2015        PMID: 25957581      PMCID: PMC4500775          DOI: 10.1093/jac/dkv114

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


Introduction

CTX-M-producing Escherichia coli are the most common type of ESBL-producing E. coli, causing hospital-associated and community infections with extensive dissemination in the environment.[1] There are few data on the community carriage of CTX-M ESBL-producing E. coli in China[2] and two studies describe greatly different carriage rates: 7% and 50.5%.[3,4] ST131 is the predominant extraintestinal pathogenic E. coli (ExPEC) clone and frequently carries CTX-M.[5] The gut is the main reservoir of ExPEC,[5] although there are only a few studies of colonization by ST131, with differences in carriage rates.[5,6] Studies on ST131 carriage, with one exception,[7] either failed to distinguish the O16-ST131 clade from the more common O25b-ST131[8] or missed the O16 subgroup.[4] Therefore, further studies are necessary to characterize O16-ST131 colonization of the digestive tracts of healthy subjects. The aim of this study was to determine the prevalence and genotype distribution of CTX-M-producing E. coli and the prevalence of ST131 and the O16/O25b subgroups in healthy subjects across a province in China.

Methods

Participants

A cross-sectional survey was conducted on healthy subjects who had routine health screening at community health service centres (CHSCs) in Hunan Province between November 2013 and January 2014. A total of 11 CHSCs were selected using a multistage stratified sampling method. In the first stage, Hunan Province was divided into four different areas (northern, eastern, western and southern Hunan) according to economic development levels and geographical location. In the second stage, 11 counties were identified, representative by population, and a single CHSC from each was selected for study. Healthy individuals (≥18 years of age) who were examined at the 11 CHSCs from November 2013 to January 2014 were given an attendee list number, which was used to identify participants on the day of visit. Every day, one individual from each centre was selected by matching one computer-generated random number to the attendance list at the centre and was invited to participate in the study. The proportion of refusals was 2.3%. Individuals were excluded if they had digestive tract diseases or had been exposed to a hospital environment or treated with antibiotics within 3 months prior to sample collection. The study was approved by the Ethics Committee of the Xiangya Hospital of Central South University (reference number ECCT 201310096). Participants provided fresh stools and informed consent on the day of visit.

ESBL-producing E. coli identification, CTX-M type and phylogenetic group

Faecal samples were plated within 24 h onto chromogenic ESBL selective medium (ChromID, bioMérieux, Marcy-l'Étoile, France). E. coli were identified using API 20E (bioMérieux). Three to five pure colonies were examined for ESBL production by the double-disc synergy test according to CLSI guidelines.[9] ESBL-producing E. coli isolates were investigated for the presence of blaCTX-M genes by multiplex PCR and sequencing as previously described.[10,11] The phylogenetic groups of E. coli were determined by quadruplex PCR.[12]

Identification of ST131

The ST131 clonal group and O16/O25b variants were identified as previously described.[13] MLST was used to resolve discrepant results (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli).

Antimicrobial susceptibility testing

For all of the ST131 isolates, three to five pure colonies were tested for antibiotic susceptibility by disc diffusion and the results were interpreted according to the breakpoints recommended by the CLSI.[9] The following antimicrobial agents were tested: ampicillin, ampicillin/sulbactam, cefazolin, ceftriaxone, ceftazidime, gentamicin, ciprofloxacin, piperacillin/tazobactam, imipenem, minocycline, nitrofurantoin, chloramphenicol and trimethoprim/sulfamethoxazole. E. coli ATCC 25922 was used as a quality control strain. Intermediate susceptibility was considered as resistant. The resistance score was calculated as previously described.[7] Isolates that were considered MDR were those resistant to at least three antimicrobial categories.

Molecular characterization of ST131

The alleles of fimH, gyrA and parC, the H30-Rx subclones, plasmid-mediated quinolone resistance (PMQR) determinants [qnrA, qnrB, qnrC, qnrS, aac(6′)-Ib-cr and qepA], virulence factor genes (n = 32) and virotypes were determined as previously described.[14-17] ST131 isolates were subjected to PFGE analysis using XbaI digestion. A PFGE dendrogram was constructed with BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) according to the unweighted pair group method based on Dice coefficients. Isolates with a Dice similarity index ≥85% were considered to belong to the same PFGE group.

Statistical analysis

Comparisons of proportions were performed using Fisher's exact test. Comparisons of antibiotic resistance scores were performed using the Mann–Whitney U-test. A P value <0.05 was considered to be statistically significant.

Results

Prevalence and genotype distribution of faecal CTX-M-producing E. coli

A total of 563 faecal samples, one sample from each participant, were analysed. The age range of the individuals (299 males and 264 females) recruited into the study was 18–83 (mean 44.3) years. Of the 563 samples collected, 287 were identified as ESBL-producing E. coli, with all strains harbouring blaCTX-M-type genes. The prevalence of CTX-M-producing E. coli was thus 51.0% (287/563 samples). Of the 287 isolates, 139 (48.4%) produced CTX-M-14, 79 (27.5%) CTX-M-15, 43 (15.0%) CTX-M-27, 11 (3.8%) CTX-M-65, 10 (3.5%) CTX-M-3, 2 (0.7%) CTX-M-24, 2 (0.7%) CTX-M-104 and 1 (0.3%) CTX-M-101. Phylogenetic analysis of the 287 CTX-M-producing E. coli strains showed that 101 (35.2%) belonged to phylogroup D, 66 (23.0%) to phylogroup A, 63 (22.0%) to phylogroup B2, 36 (12.5%) to phylogroup B1, 11 (3.8%) to phylogroup F, 7 (2.4%) to phylogroup C, 2 (0.7%) to phylogroup E and 1 (0.3%) to clade I.

E. coli ST131 clonal group and antimicrobial susceptibility

PCR analysis showed that 32 (11.1%) of the 287 CTX-M-producing isolates belonged to the ST131 clonal group, comprising 24 O16-B2-ST131 and 8 O25b-B2-ST131 isolates; only 2 isolates required full MLST. All of the 32 ST131 isolates were found to be resistant to ceftriaxone, cefazolin and ampicillin, 17 (53.1%) to ceftazidime, 10 (31.3%) to ciprofloxacin, 14 (43.8%) to gentamicin, 28 (87.5%) to ampicillin/sulbactam, 20 (62.5%) to trimethoprim/sulfamethoxazole, 8 (25.0%) to minocycline, 2 (6.3%) to piperacillin/tazobactam and 4 (12.5%) to chloramphenicol. None of the isolates was resistant to imipenem or nitrofurantoin.

E. coli ST131 characterization

Characterization of the 32 E. coli ST131 isolates is shown in Figure 1. The fimH gene was carried by all 24 O16-ST131 isolates, which were H41 lineage. In contrast, only half of the eight O25b-ST131 isolates belonged to the H41 lineage. The remaining four isolates harbouring fimH belonged to the H30 lineage, with none representing the H30-Rx sublineage. All of the O25b-ST131 isolates except one showed gyrA1AB and parC1aAB mutations; most of the O16-ST131 isolates had gyrA1A and parC1b mutations. None of the PMQR determinants was detected in any of the 32 ST131 isolates. Nine PFGE clusters with a similarity index of ≥85% were identified. Unique PFGE profiles were seen in six isolates (Figure 1).
Figure 1.

The XbaI PFGE-based dendrogram for the 32 E. coli ST131 isolates. The dendrogram was generated according to the unweighted pair group method based on Dice coefficients. O types, serogroup; FQ, fluoroquinolone phenotype (R, resistant; S, susceptible); fimH, allele of fimH (type 1 fimbrial adhesin); gyrA/parC, allele of gyrA and parC (encoding DNA gyrase and topoisomerase, respectively); 1/1b, gyrA1 (WT) combined with parC1b (one silent mutation); 1A/1b, gyrA1A (one replacement mutation, Ser83Leu) combined with parC1b; 1AB/3A, gyrA1AB (two replacement mutations, Ser83Leu and Asp87Asn) combined with parC3A (a recombined variant containing one replacement mutation Ser80Ile); 1AB/1aAB, gyrA1AB combined with parC1aAB (parC1a plus the replacement mutations Ser80Ile and Glu84Val). The 32 ST131 isolates formed one large group at the 64% similarity level. They comprised 15 PFGE groups (defined at ≥85% similarity).

The XbaI PFGE-based dendrogram for the 32 E. coli ST131 isolates. The dendrogram was generated according to the unweighted pair group method based on Dice coefficients. O types, serogroup; FQ, fluoroquinolone phenotype (R, resistant; S, susceptible); fimH, allele of fimH (type 1 fimbrial adhesin); gyrA/parC, allele of gyrA and parC (encoding DNA gyrase and topoisomerase, respectively); 1/1b, gyrA1 (WT) combined with parC1b (one silent mutation); 1A/1b, gyrA1A (one replacement mutation, Ser83Leu) combined with parC1b; 1AB/3A, gyrA1AB (two replacement mutations, Ser83Leu and Asp87Asn) combined with parC3A (a recombined variant containing one replacement mutation Ser80Ile); 1AB/1aAB, gyrA1AB combined with parC1aAB (parC1a plus the replacement mutations Ser80Ile and Glu84Val). The 32 ST131 isolates formed one large group at the 64% similarity level. They comprised 15 PFGE groups (defined at ≥85% similarity). The virulence genotypes of O16-ST131 resembled those of the O25b-ST131 isolates (Table S1, available as Supplementary data at ). All of the ST131 isolates were found to belong to virotype C.

Association of O16 and O25b subgroups with antimicrobial resistance and CTX-M type

As indicated in Table 1, the O25b-ST131 isolates had a significantly higher prevalence of resistance to ciprofloxacin compared with O16-ST131. The O16-H41 isolates were more likely to be positive for blaCTX-M-14. All of the O25b-H41 isolates produced CTX-M-15, which was not found in the O25b-H30 isolates.
Table 1.

Antimicrobial resistance and CTX-M genotypes of the 32 E. coli ST131 isolates

No. (%) of ST131 isolates
P value
O16-H41 (n = 24)O25b
O16-H41 versus O25b-H30O16-H41 versus O25b-H41O25b-H30 versus O25b-H41
H30 (n = 4)H41 (n = 4)
Antimicrobial resistance
 ciprofloxacin2 (8)4 (100)4 (100)0.0010.001
 gentamicin12 (50)2 (50)01.0000.1130.429
 minocycline4 (17)1 (25)3 (75)1.0000.0380.486
 piperacillin/tazobactam1 (4)1 (25)00.2701.0001.000
 ampicillin/sulbactam22 (92)2 (50)4 (100)0.0861.0000.429
 trimethoprim/sulfamethoxazole16 (67)4 (100)00.2950.0240.029
 imipenem000
 nitrofurantoin000
 chloramphenicol1 (4)03 (75)1.0000.0050.143
 cefazolin24 (100)4 (100)4 (100)
 ceftriaxone24 (100)4 (100)4 (100)
 ceftazidime10 (42)3 (75)4 (100)0.3110.0981.000
 ampicillin24 (100)4 (100)4 (100)
MDR11 (46)4 (100)3 (75)0.1020.5961.000
Resistance score3.4 (2–6)a4.5 (3–6)a4.5 (3–5)a0.2690.0550.760
CTX-M genotype
 CTX-M-1414 (58)2 (50)01.0000.0980.429
 CTX-M-155 (21)04 (100)1.0000.0060.029
 CTX-M-273 (13)2 (50)00.1351.0000.429
 other CTX-Mb2 (8)001.0001.000

aThe value denotes the mean and range.

bCTX-M-3 was found in one O16-ST131 isolate and CTX-M-24 was found in one O16-ST131 isolate.

Antimicrobial resistance and CTX-M genotypes of the 32 E. coli ST131 isolates aThe value denotes the mean and range. bCTX-M-3 was found in one O16-ST131 isolate and CTX-M-24 was found in one O16-ST131 isolate.

Discussion

We have found the colonization prevalence of CTX-M-producing E. coli in healthy individuals to be 51.0%, which is much higher than that reported from European countries (0.6%–11.3%).[1,18] Although a high prevalence (27.5%) of CTX-M-15 has not been observed in previous studies of community carriage from China,[3,4] our findings suggest that this worldwide dominant genotype is displacing the current genotypes (CTX-M-14 and CTX-M-27) in China. Our observation correlates with a recent report on clinical E. coli isolates across China showing 14.5% CTX-M-15 and 19.7% CTX-M-55 (a single-locus variant of CTX-M-15).[19] This emphasizes the importance of studying the human faecal resistome as many strains causing infection are derived from the gut. O25b:H4 was considered the dominant ST131 clone serotype in almost all previous studies,[5,6] whereas O16:H5, a recently identified serotype of ST131 isolates, accounted for a small subset (1%–12%) in a few countries.[5-7] However, data from China are lacking and the present study is the first to show the presence of O16-ST131 in this country. Surprisingly, we found that O16-ST131 was the predominant subset (75%) among ST131 isolates, whereas this type only accounted for 8% in France.[7] These disparities may be due to geographical or host population differences. To our knowledge, our study is the first to report that the O16 subset accounts for such a high proportion of the ST131 isolates. This finding implies that O16-ST131 may be poised to emerge as a major type of E. coli ST131 in the community in China. All of the O16-ST131 isolates were found to belong to the fimH-based H41 subclone, as reported previously.[7,13] In contrast, the O25b-ST131 isolates carried the fimH30 or H41 allele. This is the first study to show the presence of O25b-ST131 with the fimH41 allele. Multiple previous studies have documented that most O25b-ST131 isolates contain the H30 allele, with a minority containing H22 and the remainder containing one of several rarer fimH alleles, but not fimH41.[6,13] The reason for the emergence of the fimH41 allele in O25b-ST131 is not yet clear, but may be due to the homologous recombination of fimH alleles in O25b-ST131 isolates.[20] Further studies are required to elucidate and monitor the evolution of O25b-ST131 with the fimH41 allele. A limitation was that the small number of O25b-ST131 isolates restricted the broad generalizability of the characterization (especially statistical analyses) of O16-H41, O25b-H30 and O25b-H41 subgroups presented in this study. Thus, studies with larger sample sizes and more broadly distributed populations are required to further explore the characterization of these subgroups in the future. In conclusion, to our knowledge, this is the first study to report O16-ST131 as the predominant type of clonal group in ST131. Our findings indicate that future studies should focus more on O16-ST131 isolates, especially in high-incidence areas such as China.

Funding

This work was supported by the Fundamental Research Funds for the Central Universities of Central South University (2014zzts352) and by a grant from the Development and Reform Commission of Hunan Province ([2014]658).

Transparency declarations

None to declare.

Supplementary data

Table S1 is available as Supplementary data at
  19 in total

Review 1.  The changing epidemiology of resistance.

Authors:  Peter M Hawkey; Annie M Jones
Journal:  J Antimicrob Chemother       Date:  2009-09       Impact factor: 5.790

Review 2.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China.

Authors:  Bin Li; Jing-Yong Sun; Qing-Zhong Liu; Li-Zhong Han; Xin-Hong Huang; Yu-Xing Ni
Journal:  Scand J Infect Dis       Date:  2010-12-03

4.  Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.

Authors:  James R Johnson; Veronika Tchesnokova; Brian Johnston; Connie Clabots; Pacita L Roberts; Mariya Billig; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Lance B Price; Maliha Aziz; Marie-Hélène Nicolas-Chanoine; Chitrita Debroy; Ari Robicsek; Glen Hansen; Carl Urban; Joanne Platell; Darren J Trott; George Zhanel; Scott J Weissman; Brad T Cookson; Ferric C Fang; Ajit P Limaye; Delia Scholes; Sujay Chattopadhyay; David C Hooper; Evgeni V Sokurenko
Journal:  J Infect Dis       Date:  2013-01-03       Impact factor: 5.226

5.  Role of homologous recombination in adaptive diversification of extraintestinal Escherichia coli.

Authors:  Sandip Paul; Elena V Linardopoulou; Mariya Billig; Veronika Tchesnokova; Lance B Price; James R Johnson; Sujay Chattopadhyay; Evgeni V Sokurenko
Journal:  J Bacteriol       Date:  2012-11-02       Impact factor: 3.490

6.  Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics.

Authors:  Jorge Blanco; Azucena Mora; Rosalia Mamani; Cecilia López; Miguel Blanco; Ghizlane Dahbi; Alexandra Herrera; Juan Marzoa; Val Fernández; Fernando de la Cruz; Luis Martínez-Martínez; María Pilar Alonso; Marie-Hélène Nicolas-Chanoine; James R Johnson; Brian Johnston; Lorena López-Cerero; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

7.  Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany.

Authors:  Sabine Gröbner; Dirk Linke; Wolfgang Schütz; Claudia Fladerer; Johannes Madlung; Ingo B Autenrieth; Wolfgang Witte; Yvonne Pfeifer
Journal:  J Med Microbiol       Date:  2009-06-05       Impact factor: 2.472

8.  Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China.

Authors:  Su Fei Tian; Bai Yi Chen; Yun Zhuo Chu; Shuang Wang
Journal:  Can J Microbiol       Date:  2008-09       Impact factor: 2.419

9.  The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups.

Authors:  Olivier Clermont; Julia K Christenson; Erick Denamur; David M Gordon
Journal:  Environ Microbiol Rep       Date:  2012-12-24       Impact factor: 3.541

10.  Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period.

Authors:  Hong Bin Kim; Chi Hye Park; Chung Jong Kim; Eui-Chong Kim; George A Jacoby; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

View more
  21 in total

1.  [Bloodstream infections with Escherichia coli O16-ST131 and O25b-ST131: molecular epidemiology, phylogenetic analysis and antimicrobial resistance].

Authors:  Yiming Zhong; Xiaohe Zhang; Wenen Liu; Fang Yang; Qun Yan; Qingxia Liu; Yanming Li; Hongling Li; Mingxiang Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-12-30

2.  Economic Burden of Patients with Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli.

Authors:  Yuan Wang; Tingting Xiao; Yunying Zhu; Jing Ye; Kai Yang; Qixia Luo; Ping Shen; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2020-10-13       Impact factor: 4.003

3.  Whole-Genome Sequencing Identifies In Vivo Acquisition of a blaCTX-M-27-Carrying IncFII Transmissible Plasmid as the Cause of Ceftriaxone Treatment Failure for an Invasive Salmonella enterica Serovar Typhimurium Infection.

Authors:  Bruce McCollister; Cassandra V Kotter; Daniel N Frank; Taylor Washburn; Michael G Jobling
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

Authors:  Yasufumi Matsumura; Johann D D Pitout; Ryota Gomi; Tomonari Matsuda; Taro Noguchi; Masaki Yamamoto; Gisele Peirano; Rebekah DeVinney; Patricia A Bradford; Mary R Motyl; Michio Tanaka; Miki Nagao; Shunji Takakura; Satoshi Ichiyama
Journal:  Emerg Infect Dis       Date:  2016-11       Impact factor: 6.883

5.  Prevalence and characteristics of ST131 clone among unselected clinical Escherichia coli in a Chinese university hospital.

Authors:  Bin Li; Yanfang Lu; Fangjun Lan; Qingwen He; Chen Li; Yingping Cao
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-15       Impact factor: 4.887

6.  The ST131 Escherichia coli H22 subclone from human intestinal microbiota: Comparison of genomic and phenotypic traits with those of the globally successful H30 subclone.

Authors:  Marie-Hélène Nicolas-Chanoine; Marie Petitjean; Azucena Mora; Noémie Mayer; Jean-Philippe Lavigne; Olivier Boulet; Véronique Leflon-Guibout; Jorge Blanco; Didier Hocquet
Journal:  BMC Microbiol       Date:  2017-03-27       Impact factor: 3.605

7.  A putative multi-replicon plasmid co-harboring beta-lactamase genes blaKPC-2, blaCTX-M-14 and blaTEM-1 and trimethoprim resistance gene dfrA25 from a Klebsiella pneumoniae sequence type (ST) 11 strain in China.

Authors:  Yu Tang; Pinghua Shen; Wei Liang; Jialin Jin; Xiaofei Jiang
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

8.  Combined Analysis of Variation in Core, Accessory and Regulatory Genome Regions Provides a Super-Resolution View into the Evolution of Bacterial Populations.

Authors:  Alan McNally; Yaara Oren; Darren Kelly; Ben Pascoe; Steven Dunn; Tristan Sreecharan; Minna Vehkala; Niko Välimäki; Michael B Prentice; Amgad Ashour; Oren Avram; Tal Pupko; Ulrich Dobrindt; Ivan Literak; Sebastian Guenther; Katharina Schaufler; Lothar H Wieler; Zong Zhiyong; Samuel K Sheppard; James O McInerney; Jukka Corander
Journal:  PLoS Genet       Date:  2016-09-12       Impact factor: 5.917

9.  Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli.

Authors:  N Stoesser; A E Sheppard; G Peirano; L W Anson; L Pankhurst; R Sebra; H T T Phan; A Kasarskis; A J Mathers; T E A Peto; P Bradford; M R Motyl; A S Walker; D W Crook; J D Pitout
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

10.  Epidemic Potential of Escherichia coli O16:H41-ST131: Compared with Pandemic O25b:H30-ST131 Lineage.

Authors:  Shengcen Zhang; Qianwen Zhang; Jiangqing Huang; Yingping Cao; Zhichang Zhao; Bin Li
Journal:  Infect Drug Resist       Date:  2021-07-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.